organization · Reporting owner

BB BIOTECH AG

Disclosed activity across 7 companies

Tapewire entity: 81733
SEC CIK: 0000924223

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Cidara Therapeutics, Inc.CDTX · Entity 69639	10% owner	November 15, 2017	November 16, 2017
Esperion Therapeutics, Inc.ESPR · Entity 30796	10% owner	May 24, 2021	May 26, 2021
MACROGENICS INCMGNX · Entity 6104	10% owner	October 02, 2023	October 04, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Cidara Therapeutics, Inc.

Report date November 15, 2017 · Filed November 16, 2017

Jointly reported with BIOTECH TARGET N V

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,295,272	Reported balance After 2017-11-15 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2017-11-15 · Purchase · Acquired 60,000 · Balance 2,295,272

Esperion Therapeutics, Inc.

Report date May 24, 2021 · Filed May 26, 2021

Jointly reported with BIOTECH TARGET N V

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	4,477,964	Reported balance After 2021-05-24 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-05-24 · Purchase · Acquired 100,000 · Balance 4,477,964

MACROGENICS INC

Report date October 02, 2023 · Filed October 04, 2023

Jointly reported with BIOTECH TARGET N V

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	9,929,963	Reported balance After 2023-10-02 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2023-10-02 · Purchase · Acquired 150,000 · Balance 9,929,963

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Black Diamond Therapeutics, Inc.

Report date March 19, 2025 · Filed March 21, 2025

Jointly reported with BIOTECH GROWTH N V

Section 16 reporting ended · disclosed 2025-03-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	7,517,839	Reported balance After 2025-03-19 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-03-19 · Sale · Disposed 1,000,000 · Balance 7,517,839
Common StockSEC Table I · non-derivative	Direct	7,217,839	Reported balance After 2025-03-19 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2025-03-19 · Sale · Disposed 300,000 · Balance 7,217,839
Common StockSEC Table I · non-derivative	Direct	6,217,839	Reported balance After 2025-03-19 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2025-03-19 · Sale · Disposed 1,000,000 · Balance 6,217,839
Common StockSEC Table I · non-derivative	Direct	4,217,839	Reported balance After 2025-03-19 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2025-03-19 · Sale · Disposed 2,000,000 · Balance 4,217,839
Common StockSEC Table I · non-derivative	Direct	3,817,839	Reported balance After 2025-03-19 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2025-03-19 · Sale · Disposed 400,000 · Balance 3,817,839
Common StockSEC Table I · non-derivative	Direct	3,233,547	Reported balance After 2025-03-19 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 6 · 2025-03-19 · Sale · Disposed 584,292 · Balance 3,233,547
Common StockSEC Table I · non-derivative	Direct	2,733,547	Reported balance After 2025-03-19 transaction · row 7 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 7 · 2025-03-19 · Sale · Disposed 500,000 · Balance 2,733,547

ESSA Pharma Inc.

Report date November 01, 2024 · Filed November 05, 2024

Jointly reported with BIOTECH GROWTH N V

Section 16 reporting ended · disclosed 2024-11-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	5,879,583	Reported balance After 2024-11-01 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2024-11-01 · Sale · Disposed 2,000,000 · Balance 5,879,583
Common SharesSEC Table I · non-derivative	Direct	3,879,583	Reported balance After 2024-11-01 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2024-11-01 · Sale · Disposed 2,000,000 · Balance 3,879,583
Common SharesSEC Table I · non-derivative	Direct	1,879,583	Reported balance After 2024-11-01 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2024-11-01 · Sale · Disposed 2,000,000 · Balance 1,879,583
Common SharesSEC Table I · non-derivative	Direct	0	Reported balance After 2024-11-01 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2024-11-01 · Sale · Disposed 1,879,583 · Balance 0

Molecular Templates, Inc.

Report date November 14, 2024 · Filed November 19, 2024

Jointly reported with BIOTECH TARGET N V

Section 16 reporting ended · disclosed 2024-11-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2024-11-14 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2024-11-14 · Sale · Disposed 1,279,820 · Balance 0
Prefunded Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	134,667	Reported balance After 2024-04-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-04-02 · Purchase · Acquired 134,667 · Balance 134,667 F1: The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 9.99% of the number of the shares of Common Stock outstanding immediately following such exercise.
Common Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.35 · Expires 2029-04-02	Direct	769,334	Reported balance After 2024-04-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-04-02 · Purchase · Acquired 769,334 · Balance 769,334 F1: The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 9.99% of the number of the shares of Common Stock outstanding immediately following such exercise.

Filing footnotes · ownership attribution and instrument terms

F1: The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 9.99% of the number of the shares of Common Stock outstanding immediately following such exercise.

Radius Health, Inc.

Report date August 15, 2022 · Filed August 30, 2022

Jointly reported with BIOTECH TARGET N V

Section 16 reporting ended · disclosed 2022-08-30. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2022-08-11 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2022-08-11 · Other · Disposed 8,733,538 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of June 23, 2022, by and among the Issuer, Ginger Acquisition, Inc. ("Parent") and Ginger Merger Sub, Inc. ("Purchaser"), the Issuer merged with and into Purchaser on August 15, 2022, following a tender offer by Purchaser (the "Offer") to purchase each outstanding share of the Issuer's common stock in exchange for (i) $10.00, in cash, without interest and less applicable tax withholdings, plus (ii) one contractual contingent value right, which represents the right to receive a contingent payment of $1.00 (without interest thereon) upon the satisfaction of certain conditions (collectively, the "Offer Price"). Pursuant to the Merger Agreement and the Offer, the Purchaser acquired all of the shares of the Company held by the Reporting Persons and merged with and into the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of June 23, 2022, by and among the Issuer, Ginger Acquisition, Inc. ("Parent") and Ginger Merger Sub, Inc. ("Purchaser"), the Issuer merged with and into Purchaser on August 15, 2022, following a tender offer by Purchaser (the "Offer") to purchase each outstanding share of the Issuer's common stock in exchange for (i) $10.00, in cash, without interest and less applicable tax withholdings, plus (ii) one contractual contingent value right, which represents the right to receive a contingent payment of $1.00 (without interest thereon) upon the satisfaction of certain conditions (collectively, the "Offer Price"). Pursuant to the Merger Agreement and the Offer, the Purchaser acquired all of the shares of the Company held by the Reporting Persons and merged with and into the Issuer.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
April 18, 2022 Filed Apr 20, 2022 16:56 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	PurchaseCommon Stock	150,000	$3.29	$493,935.00	Disclosure SEC source: 0000899243-22-015145 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,138,402 Read SEC document
April 13, 2022 Filed Apr 14, 2022 16:09 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	PurchaseCommon Stock	102,556	$3.57	$366,217.22	Disclosure SEC source: 0000899243-22-014768 · doc4.xml · nonDerivative · entry 2 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,988,402 Read SEC document
April 12, 2022 Filed Apr 14, 2022 16:09 UTC	Black Diamond Therapeutics, Inc. BDTX · Entity 6669	PurchaseCommon Stock	150,000	$3.42	$513,600.00	Disclosure SEC source: 0000899243-22-014768 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,885,846 Read SEC document
January 06, 2022 Filed Jan 7, 2022 16:33 UTC	Radius Health, Inc. RDUS · Entity 124173	PurchaseCommon Stock	300,000	$6.31	$1,894,410.00	Disclosure SEC source: 0000899243-22-001316 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,255,714 Read SEC document
January 06, 2022 Filed Jan 10, 2022 16:49 UTC	Molecular Templates, Inc. MTEM · Entity 85987	PurchaseCommon Stock	200,000	$4.04	$807,180.00	Disclosure SEC source: 0000899243-22-001433 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,992,003 Read SEC document
January 05, 2022 Filed Jan 7, 2022 16:33 UTC	Radius Health, Inc. RDUS · Entity 124173	PurchaseCommon Stock	250,000	$6.30	$1,574,650.00	Disclosure SEC source: 0000899243-22-001316 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,955,714 Read SEC document
November 19, 2021 Filed Nov 23, 2021 17:29 UTC	MACROGENICS INC MGNX · Entity 6104	PurchaseCommon Stock	200,000	$18.50	$3,700,320.00	Disclosure SEC source: 0000899243-21-045703 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,275,564 Read SEC document
September 29, 2021 Filed Sep 30, 2021 19:09 UTC	MACROGENICS INC MGNX · Entity 6104	PurchaseCommon Stock	100,000	$20.47	$2,047,460.00	Disclosure SEC source: 0000899243-21-038368 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,075,564 Read SEC document
September 29, 2021 Filed Oct 1, 2021 14:34 UTC	Radius Health, Inc. RDUS · Entity 124173	PurchaseCommon Stock	100,000	$12.95	$1,294,500.00	Disclosure SEC source: 0000899243-21-038590 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,705,714 Read SEC document
September 28, 2021 Filed Sep 30, 2021 19:09 UTC	MACROGENICS INC MGNX · Entity 6104	PurchaseCommon Stock	100,000	$20.64	$2,063,960.00	Disclosure SEC source: 0000899243-21-038368 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,975,564 Read SEC document
September 22, 2021 Filed Sep 24, 2021 15:58 UTC	Radius Health, Inc. RDUS · Entity 124173	PurchaseCommon Stock	150,000	$12.28	$1,841,280.00	Disclosure SEC source: 0000899243-21-037557 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,605,714 Read SEC document
September 21, 2021 Filed Sep 23, 2021 15:50 UTC	Molecular Templates, Inc. MTEM · Entity 85987	PurchaseCommon Stock	750,000	$6.00	$4,500,000.00	Disclosure SEC source: 0000899243-21-037292 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,792,003 Read SEC document
September 17, 2021 Filed Sep 20, 2021 16:21 UTC	MACROGENICS INC MGNX · Entity 6104	PurchaseCommon Stock	200,000	$19.93	$3,986,680.00	Disclosure SEC source: 0000899243-21-036543 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,875,564 Read SEC document
September 16, 2021 Filed Sep 20, 2021 16:21 UTC	MACROGENICS INC MGNX · Entity 6104	PurchaseCommon Stock	400,000	$20.94	$8,376,800.00	Disclosure SEC source: 0000899243-21-036543 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,675,564 Read SEC document
September 16, 2021 Filed Sep 20, 2021 16:17 UTC	Molecular Templates, Inc. MTEM · Entity 85987	PurchaseCommon Stock	100,000	$6.13	$613,000.00	Disclosure SEC source: 0000899243-21-036541 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,042,003 Read SEC document
August 18, 2021 Filed Aug 20, 2021 16:43 UTC	ESSA Pharma Inc. EPIX · Entity 15763	PurchaseCommon Shares	250,000	$8.88	$2,218,800.00	Disclosure SEC source: 0000899243-21-033765 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,015,814 Read SEC document
July 27, 2021 Filed Jul 28, 2021 16:23 UTC	Molecular Templates, Inc. MTEM · Entity 85987	PurchaseCommon Stock	75,000	$7.09	$531,840.00	Disclosure SEC source: 0000899243-21-030317 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,942,003 Read SEC document
July 26, 2021 Filed Jul 28, 2021 16:23 UTC	Molecular Templates, Inc. MTEM · Entity 85987	PurchaseCommon Stock	80,000	$7.00	$559,816.00	Disclosure SEC source: 0000899243-21-030317 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,867,003 Read SEC document
July 20, 2021 Filed Jul 21, 2021 18:02 UTC	Molecular Templates, Inc. MTEM · Entity 85987	PurchaseCommon Stock	125,000	$7.13	$891,675.00	Disclosure SEC source: 0000899243-21-029181 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,787,003 Read SEC document
July 19, 2021 Filed Jul 21, 2021 18:02 UTC	Molecular Templates, Inc. MTEM · Entity 85987	PurchaseCommon Stock	119,382	$6.96	$830,827.09	Disclosure SEC source: 0000899243-21-029181 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,662,003 Read SEC document
June 21, 2021 Filed Jun 23, 2021 17:33 UTC	MACROGENICS INC MGNX · Entity 6104	PurchaseCommon Stock	75,000	$21.74	$1,630,170.00	Disclosure SEC source: 0000899243-21-025485 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,275,564 Read SEC document
June 16, 2021 Filed Jun 17, 2021 18:54 UTC	MACROGENICS INC MGNX · Entity 6104	PurchaseCommon Stock	100,000	$21.04	$2,104,390.00	Disclosure SEC source: 0000899243-21-024412 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,200,564 Read SEC document
June 15, 2021 Filed Jun 17, 2021 18:54 UTC	MACROGENICS INC MGNX · Entity 6104	PurchaseCommon Stock	75,000	$20.53	$1,539,615.00	Disclosure SEC source: 0000899243-21-024412 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,100,564 Read SEC document
May 24, 2021 Filed May 26, 2021 15:53 UTC	Esperion Therapeutics, Inc. ESPR · Entity 30796	PurchaseCommon Stock	100,000	$20.22	$2,021,620.00	Disclosure SEC source: 0000899243-21-020706 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,477,964 Read SEC document
May 19, 2021 Filed May 21, 2021 18:06 UTC	Esperion Therapeutics, Inc. ESPR · Entity 30796	PurchaseCommon Stock	200,000	$20.37	$4,073,960.00	Disclosure SEC source: 0000899243-21-020330 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,377,964 Read SEC document
May 06, 2021 Filed May 7, 2021 19:23 UTC	Esperion Therapeutics, Inc. ESPR · Entity 30796	PurchaseCommon Stock	80,000	$20.57	$1,645,632.00	Disclosure SEC source: 0000899243-21-018635 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,177,964 Read SEC document
May 05, 2021 Filed May 7, 2021 19:23 UTC	Esperion Therapeutics, Inc. ESPR · Entity 30796	PurchaseCommon Stock	150,000	$20.02	$3,002,850.00	Disclosure SEC source: 0000899243-21-018635 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,097,964 Read SEC document
April 19, 2021 Filed Apr 21, 2021 15:22 UTC	Molecular Templates, Inc. MTEM · Entity 85987	PurchaseCommon Stock	40,852	$8.08	$329,941.18	Disclosure SEC source: 0000899243-21-016530 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,542,621 Read SEC document
April 15, 2021 Filed Apr 19, 2021 17:14 UTC	Molecular Templates, Inc. MTEM · Entity 85987	PurchaseCommon Stock	150,000	$8.62	$1,292,655.00	Disclosure SEC source: 0000899243-21-016175 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,501,769 Read SEC document
April 14, 2021 Filed Apr 15, 2021 16:26 UTC	Molecular Templates, Inc. MTEM · Entity 85987	PurchaseCommon Stock	150,000	$8.37	$1,256,040.00	Disclosure SEC source: 0000899243-21-015925 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,351,769 Read SEC document
April 13, 2021 Filed Apr 15, 2021 16:26 UTC	Molecular Templates, Inc. MTEM · Entity 85987	PurchaseCommon Stock	100,000	$7.81	$780,970.00	Disclosure SEC source: 0000899243-21-015925 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,201,769 Read SEC document
April 12, 2021 Filed Apr 13, 2021 19:51 UTC	Molecular Templates, Inc. MTEM · Entity 85987	PurchaseCommon Stock	50,000	$8.02	$400,830.00	Disclosure SEC source: 0000899243-21-015608 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,101,769 Read SEC document
April 09, 2021 Filed Apr 13, 2021 19:51 UTC	Molecular Templates, Inc. MTEM · Entity 85987	PurchaseCommon Stock	235,664	$8.23	$1,939,632.55	Disclosure SEC source: 0000899243-21-015608 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,051,769 Read SEC document
April 08, 2021 Filed Apr 9, 2021 17:52 UTC	Molecular Templates, Inc. MTEM · Entity 85987	PurchaseCommon Stock	300,000	$8.22	$2,466,660.00	Disclosure SEC source: 0000899243-21-015470 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,816,105 Read SEC document
April 07, 2021 Filed Apr 9, 2021 17:52 UTC	Molecular Templates, Inc. MTEM · Entity 85987	PurchaseCommon Stock	200,000	$8.24	$1,648,160.00	Disclosure SEC source: 0000899243-21-015470 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,516,105 Read SEC document
April 05, 2021 Filed Apr 7, 2021 17:13 UTC	Molecular Templates, Inc. MTEM · Entity 85987	PurchaseCommon Stock	200,000	$9.44	$1,887,100.00	Disclosure SEC source: 0000899243-21-015196 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,316,105 Read SEC document
March 29, 2021 Filed Mar 31, 2021 17:44 UTC	Molecular Templates, Inc. MTEM · Entity 85987	PurchaseCommon Stock	80,000	$11.45	$915,848.00	Disclosure SEC source: 0000899243-21-014121 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,116,105 Read SEC document
February 24, 2021 Filed Feb 25, 2021 19:46 UTC	Molecular Templates, Inc. MTEM · Entity 85987	PurchaseCommon Stock	75,000	$11.48	$860,835.00	Disclosure SEC source: 0000899243-21-008183 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,036,105 Read SEC document
February 23, 2021 Filed Feb 25, 2021 19:46 UTC	Molecular Templates, Inc. MTEM · Entity 85987	PurchaseCommon Stock	235,004	$11.29	$2,653,030.66	Disclosure SEC source: 0000899243-21-008183 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,961,105 Read SEC document
February 18, 2021 Filed Feb 19, 2021 22:28 UTC	Molecular Templates, Inc. MTEM · Entity 85987	PurchaseCommon Stock	1,185,770	$12.65	$14,999,990.50	Disclosure SEC source: 0000899243-21-007418 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,726,101 Read SEC document
February 01, 2021 Filed Feb 3, 2021 18:33 UTC	Molecular Templates, Inc. MTEM · Entity 85987	PurchaseCommon Stock	80,000	$11.69	$935,344.00	Disclosure SEC source: 0000899243-21-004636 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,540,331 Read SEC document
January 29, 2021 Filed Feb 1, 2021 21:58 UTC	Molecular Templates, Inc. MTEM · Entity 85987	PurchaseCommon Stock	80,000	$11.94	$955,000.00	Disclosure SEC source: 0000899243-21-003875 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,460,331 Read SEC document
December 10, 2020 Filed Dec 11, 2020 17:36 UTC	Molecular Templates, Inc. MTEM · Entity 85987	PurchaseCommon Stock	170,000	$8.18	$1,391,416.00	Disclosure SEC source: 0000899243-20-033533 · doc4.xml · nonDerivative · entry 3 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,380,331 Read SEC document
December 10, 2020 Filed Dec 11, 2020 17:36 UTC	Molecular Templates, Inc. MTEM · Entity 85987	PurchaseCommon Stock	150,000	$8.39	$1,258,425.00	Disclosure SEC source: 0000899243-20-033533 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,210,331 Read SEC document
December 09, 2020 Filed Dec 11, 2020 17:36 UTC	Molecular Templates, Inc. MTEM · Entity 85987	PurchaseCommon Stock	125,000	$8.62	$1,077,600.00	Disclosure SEC source: 0000899243-20-033533 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,060,331 Read SEC document
November 10, 2020 Filed Nov 12, 2020 11:30 UTC	Molecular Templates, Inc. MTEM · Entity 85987	PurchaseCommon Stock	80,000	$9.16	$732,472.00	Disclosure SEC source: 0000899243-20-030775 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,935,331 Read SEC document
November 09, 2020 Filed Nov 12, 2020 11:30 UTC	Molecular Templates, Inc. MTEM · Entity 85987	PurchaseCommon Stock	80,000	$9.05	$724,144.00	Disclosure SEC source: 0000899243-20-030775 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,855,331 Read SEC document
November 06, 2020 Filed Nov 9, 2020 21:09 UTC	Molecular Templates, Inc. MTEM · Entity 85987	PurchaseCommon Stock	470,335	$8.33	$3,919,960.02	Disclosure SEC source: 0000899243-20-030625 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,775,331 Read SEC document
November 05, 2020 Filed Nov 9, 2020 21:09 UTC	Molecular Templates, Inc. MTEM · Entity 85987	PurchaseCommon Stock	75,000	$10.86	$814,230.00	Disclosure SEC source: 0000899243-20-030625 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,304,996 Read SEC document
November 05, 2020 Filed Nov 9, 2020 16:29 UTC	Radius Health, Inc. RDUS · Entity 124173	PurchaseCommon Stock	100,000	$14.26	$1,426,230.00	Disclosure SEC source: 0000899243-20-030614 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,455,714 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.